Tasos Konidaris - 12 Mar 2024 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Role
Executive Vice President & CFO
Signature
/s/ Denis Butkovic, Attorney-in-Fact
Issuer symbol
AMRX
Transactions as of
12 Mar 2024
Transactions value $
-$163,495
Form type
4
Date filed
14 Mar 2024, 16:17
Previous filing
05 Mar 2024
Next filing
04 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMRX Class A Common Stock Options Exercise +87.7K +18.65% 558K 12 Mar 2024 Direct F1, F2
transaction AMRX Class A Common Stock Tax liability -$163K -30.8K -5.52% $5.31 527K 12 Mar 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMRX Restricted Stock Units Options Exercise $0 -87.7K -100% $0.00* 0 12 Mar 2024 Class A Common Stock 87.7K Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F3 Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
F4 On March 12, 2020, the reporting person was granted 350,877 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.